Although traditional pharmacological approaches improve outcomes in disease management for allergic asthma, these fail to modify the underlying immune responses. Allergen immunotherapy remains the only etiological therapy for the treatment of respiratory allergies for which clinical efficacy has been demonstrated through several well-controlled studies. In this review, we examine evidence from the past 5 years regarding the impact of allergen immunotherapy on allergic asthma to inform practitioners and stimulate further discussion and research.
Keywords: allergen immunotherapy (AIT); allergic asthma; mechanisms; omalizumab; subcutaneous immunotherapy (SCIT); sublingual immunotherapy (SLIT).